Adipose-derived stromal cells: Their identity and uses in clinical trials, an update
Adipose-derived stromal cells: Their identity and uses in clinical trials, an update作者机构：Université de Toulouse UPS UMR 5241 Métabolisme Plasticité et Mitochondrie BP 84225 F-31 432 Toulouse Cedex 4 France CNRS UMR 5241 Métabolisme Plasticité et Mitochondrie BP 84 225 F-31 432 Toulouse France Laboratoire d'Hématologie CHU Toulouse France
出 版 物：《World Journal of Stem Cells》 (世界干细胞杂志（英文版）（电子版）)
年 卷 期：2011年第3卷第4期
页 面：25-33页
学科分类：1001[医学-基础医学(可授医学、理学学位)] 100101[医学-人体解剖与组织胚胎学] 10[医学]
主 题：Mesenchymal stem cells Stroma cells Cell therapy White adipose tissue
摘 要：In adults, adipose tissue is abundant and can be easily sampled using liposuction. Largely involved in obesity and associated metabolic disorders, it is now described as a reservoir of immature stromal cells. These cells, called adipose-derived stromal cells (ADSCs) must be distinguished from the crude stromal vascular fraction (SVF) obtained after digestion of adipose tissue. ADSCs share many features with mesenchymal stem cells derived from bone marrow, including paracrine activity, but they also display some specific features, including a greater angiogenic potential. Their angiogenic properties as well as their paracrine activity suggest a putative tumor-promoting role for ADSCs although contradictory data have been published on this issue. Both SVF cells and ADSCs are currently being investigated in clinical trials in several fields (chronic inflammation, ischemic diseases, etc. ). Apart from a phase Ⅲ trial on the treatment of fistula,most of these are in phaseⅠand use autologous cells. In the near future, the end results of these trials should provide a great deal of data on the safety of ADSC use.
维普期刊数据库